News
Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of ...
Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...
The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...
Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...
Pharmaceutical stocks are making headlines today, after two U.S.-based sector heavyweights stepped into the earnings ...
A Cardington man was indicted Thursday on 41 counts in a case involving pandering sexually oriented materials involving ...
Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...
Oppenheimer lowered the firm’s price target on Gilead (GILD) to $125 from $132 and keeps an Outperform rating on the shares. The firm notes ...
The Gilead Road Bridge over I-77 in Huntersville, NC, will be closed from May 2 at 9 p.m. to May 5 at 6 a.m. for interchange ...
WARNING: The following story contains spoilers about the fifth episode of The Handmaid's Tale's sixth and final season, ...
"The Handmaid's Tale" may be coming to an end, but the world of Gilead is not with a sequel, "The Testaments," in production ...
The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback